18F-Fluorocholine PET/CT in Medullary Thyroid Cancer

Launched by UNIVERSITY MEDICAL CENTRE LJUBLJANA · Aug 20, 2018

Keywords

ClinConnect Summary

Medullary thyroid cancer (MTC) is a relatively rare type of cancer that represents up to 10% of all primary thyroid cancers. It is a neuroendocrine tumour derived from parafollicular C-cells of the thyroid. It occurs either sporadically or in a hereditary form as a component of the type 2 multiple endocrine neoplasia (MEN) syndromes, MEN2A and MEN2B, and the related syndrome, familial MTC (FMTC).

Currently, the diagnosis of MTC is suspected based on the results of fine-needle aspiration (FNA) cytology, immunohistochemical analysis and elevated laboratory values of tumour markers calcitonin...

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Patients with medullary thyroid cancer (sporadic or hereditary form).
• • Patients with newly diagnosed MTC for primary staging (based on fine needle aspiration cytology results).
• • Patients with suspicion of MTC recurrence for re-staging (based on biochemical, conventional imaging or clinical examination).
• • Patients with metastatic MTC on systemic therapy for disease activity assessment.
• Exclusion Criteria:
• • Pregnancy.
• • Patient with any PET/CT-scan exam contraindication (eg. severe claustrophobia).